Creso to release immunity boosting CBD hemp teas in Q3
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
The $9.9 million capped Australian-listed Creso Pharma Limited (ASX: CPH) is set to release CBD hemp teas in Q3 2020.
Creso is looking to expand its footprint in the health and wellness cannabis sector, with the market on track to grow to US23.7 Billion by 2023, according to the Brightfield Group.
Creso already has a range of human and animal products in the wellness sector, so the release of its hemp tea will expand its available product line.
This range of CBD hemp teas is described as supporting immunity levels and will be distributed globally through different commercial partners.
The release of this product, also gives Creso access to the broader tea market, which was valued at $52.1 billion in 2018 and is estimated to reach $81.6 billion by 2026, registering a CAGR of 5.8% from 2019 to 2026.
In 2018, the Asia-Pacific region accounted for more than half of the share in the global tea market and is expected to grow at a CAGR of 6.5% throughout the forecast period, so Creso could be well placed as an Australian-listed company to tap into this demand.
Successful testing leads to release
Creso has successfully developed and tested its first cannaQIX® CBD hemp instant tea to be available on the international markets in Q3.
This follows the breakthrough development its first water-soluble microgranulated hemp plant granules product to expand the cannaQIX® human health product line earlier in the year.
As with the water-soluble microgranulated hemp plant granules product, this new product was developed together with Switzerland’s Domaco Pharma based on the anibidiol® granules technology and will be used to extend Creso’s successful cannaQIX® product line.
cannaQIX® CBD instant hemp tea is offered in two product versions:
- cannaQIX® CBD instant hemp tea formulated with CBD hemp, zinc, selene, elderberry, and vitamins to support the immune system and manage stress;
- cannaQIX® NITE CBD instant hemp tea formulated with CBD hemp, zinc, selene, elderberry, lemon balm and vitamins to strengthen the immune system and support better sleep.
This new products use natural hemp plant and provide an “entourage effect” in which various compounds work together to particularly strengthen the immune system.
“With the achievement of this innovation we address customers’ needs for a natural easy to use product to support the immune system,” Dr. Gian Trepp, R&D/Commercial Director of Creso Pharma said.
The entourage effect has received considerable attention in the cannabis industry. It is also a critical factor in the food and beverage industry where multiple different molecules co-create a person’s perception of taste, smell, mouthfeel, and other sensations.
Creso Pharma plans to distribute the new products globally with different commercial partners in several countries and expects that the products will be ready for launch in Q3 2020.
Dr. Miri Halperin Wernli, Co-Founder and CEO of Creso Pharma commented on this new development, “We are looking forward to enter the markets with our new cannaQIX® CBD intstant hemp teas, as there is an increasing demand for easy to use natural products to help strengthen the immune system, particularly given the challenging healthcare times we are facing.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
